Moberg Pharma increases efficiency and reduces costs through expanded partnership with Emerson Group

Moberg Pharma AB (OMX: MOB) announced that it entered into a services agreement
with Emerson Healthcare, a division of  Emerson Group, who will provide certain
logistical services and all order to cash functions for retailer and wholesaler
customers in the U.S. Along with the outsourcing agreement, the companies are
entering into a new Sales Representation Agreement with Emerson Group. The two
agreements will result in significant savings in sales and administrative costs
for Moberg.
Moberg’s U.S. subsidiary has contracted with Emerson Group for its contract
sales functions since 2007. Outsourcing logistical services to Emerson
Healthcare will also create savings and efficiencies for Moberg’s retailer
customers, by consolidating ordering, receivable, inventory and chargeback
functions with the other Emerson clients. Emerson currently provides the same
functions for over 200 brands with retail sales of over $1 billion. The
agreements take effect on December 1, 2014.

“We are pleased to expand the successful relationship with Emerson. Outsourcing
these services will provide immediate savings in freight costs, as well as
reducing focus of internal resources on non-value added activities. Under this
new model our U.S. team will be able to spend more time and effort on activities
that directly drive sales and build brand equity,” said Peter Wolpert, CEO of
Moberg Pharma AB.

“We are excited about Moberg’s model to drive growth through a unique
combination of innovation and brand equity. The expanded partnership unlocks
additional value and enables us to support Moberg’s growth in the U.S. in an
excellent way,” said Scott Emerson, President and Founder of Emerson Group.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 am (CET) on November 4, 2014.
For additional information contact:
Peter Wolpert, CEO
Telephone: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergpharma.se

Peter Östling, IR
Mobil: +46 (0)76 – 314 09 78
Email: peter.ostling@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
a direct sales and marketing organization in the U.S. and an extensive
distributor network in more than 40 countries. The company’s OTC portfolio
includes the brands Kerasal®, Jointflex®, Kerasal Nail™, Domeboro®, Vanquish®,
and Fergon®. Kerasal Nail™ (Nalox™ in certain ex-U.S. markets) is the leading
product for the treatment of nail disorders in the U.S. and Nordic market. The
current portfolio will be supplemented by the acquisition and in-licensing of
additional products as well as product development with a focus on innovative
drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and
New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list
of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please
visit: www.mobergpharma.com.

About Emerson Healthcare
Emerson Healthcare (EHC) is a complete “order to cash” provider. It´s technology
platform reduces costs for the retailer and manufacturer. EHC is a vendor with
over 200 North American retailers. Winning Vendor of the Year awards with
retailers like Walmart and Rite Aid.